Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 981 to 990 of 1543 total matches.
Alirocumab (Praluent) to Lower LDL-Cholesterol
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015 (Issue 1475)
.,
atorvastatin 40-80 mg), which generally results in
114
The Medical Letter ® Vol. 57 (1475) August 17, 2015 ...
The FDA has approved the subcutaneously injected
PCSK9 (proprotein convertase subtilisin kexin type 9)
inhibitor alirocumab (Praluent – Sanofi/Regeneron)
as an adjunct to diet and maximally tolerated
statin therapy for adults with heterozygous familial
hypercholesterolemia (HeFH) or clinical atherosclerotic
cardiovascular disease who require additional lowering
of LDL-cholesterol (LDL-C). It was not approved for
general use in statin-intolerant patients. Alirocumab
is the first PCSK9 inhibitor to be approved in the US.
Evolocumab (Repatha – Amgen), another PCSK9
inhibitor, was...
Tiotropium/Olodaterol (Stiolto Respimat) for COPD
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
in trial
2). Responses were maintained for 52 weeks.
162
The Medical Letter ® Vol. 57 (1482) November 23 ...
The FDA has approved a fixed-dose, orally inhaled
combination of the long-acting anticholinergic tiotropium
and the long-acting beta2-adrenergic agonist
olodaterol (Stiolto Respimat — Boehringer Ingelheim)
for long-term, once-daily, maintenance treatment of
airflow obstruction in chronic obstructive pulmonary
disease (COPD). It is not approved for treatment of acute
exacerbations of COPD or for treatment of asthma.
Tiotropium (Spiriva Handihaler, Spiriva Respimat)
and olodaterol (Striverdi Respimat) are also available
separately for once-daily treatment of...
Genvoya - A New 4-Drug Combination for HIV
The Medical Letter on Drugs and Therapeutics • Feb 15, 2016 (Issue 1488)
improvements in BMD at the spine
(+1.56% vs -0.44%) and hip (+1.47% vs -0.34%).7
20
The Medical Letter ® Vol ...
The FDA has approved Genvoya (Gilead), a fixed-dose
combination of the integrase strand transfer
inhibitor (INSTI) elvitegravir, the pharmacokinetic
enhancer cobicistat, and the nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide, for treatment of HIV-1 infection in patients ≥12 years old. This is the first
approval for tenofovir alafenamide (TAF), a tenofovir
prodrug. Stribild, a fixed-dose combination of
elvitegravir, cobicistat, emtricitabine, and tenofovir
disoproxil fumarate (TDF), was approved in 2012.
Lesinurad (Zurampic) for Gout-Associated Hyperuricemia
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016 (Issue 1508)
The Medical Letter ® Vol. 58 (1508) November 21, 2016
DRUG INTERACTIONS — Lesinurad is metabolized
by CYP2C9 ...
The FDA has approved lesinurad (Zurampic –
Ironwood), a uric acid transporter 1 (URAT1)
inhibitor, for adjunctive treatment of gout-associated
hyperuricemia in patients whose serum uric acid
levels fail to reach goal with xanthine oxidase
inhibitor monotherapy.
Inflectra - An Infliximab Biosimilar
The Medical Letter on Drugs and Therapeutics • Jan 30, 2017 (Issue 1513)
, and then
every 8 weeks was compared to the same dosage of
24
The Medical Letter ® Vol. 59 (1513) January 30 ...
The FDA has approved infliximab-dyyb (Inflectra –
Pfizer; marketed as Remsima in some countries), as a
biosimilar of the TNF inhibitor infliximab (Remicade).
Infliximab-dyyb was approved in the European Union
(EU) in 2013 and in Canada in 2014. It is the second
biosimilar to be approved by the FDA. Filgastrim-sndz
(Zarxio), a recombinant human granulocyte colony-stimulating
factor, was the first.
Lofexidine (Lucemyra) for Opioid Withdrawal
The Medical Letter on Drugs and Therapeutics • Jul 16, 2018 (Issue 1551)
discontinuation of lofexidine, however, can cause
marked rebound hypertension.
116
The Medical Letter ® Vol. 60 ...
The FDA has approved lofexidine (Lucemyra – US
WorldMeds/Salix), a centrally acting alpha2 receptor
agonist, to manage withdrawal symptoms in adults
abruptly stopping opioid use. Available in the UK since
1992, lofexidine is the first nonopioid to be approved
in the US for management of opioid withdrawal
symptoms. Clonidine (Catapres, and generics), another
central alpha2 receptor agonist, has been used off-label
for this indication for many years.
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019 (Issue 1563)
The Medical Letter ® Vol. 61 (1563) January 14, 2019
guselkumab, tildrakizumab has not been associated ...
Tildrakizumab-asmn (Ilumya – Sun), an interleukin
(IL)-23 antagonist, has been approved by the FDA for
treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy or
phototherapy. Tildrakizumab is the second selective
IL-23 antagonist to be approved for this indication;
guselkumab (Tremfya) was the first.
Dupilumab (Dupixent) for Asthma
The Medical Letter on Drugs and Therapeutics • Jan 14, 2019 (Issue 1563)
was effective irrespective of baseline blood
7
The Medical Letter ® Vol. 61 (1563) January 14, 2019 ...
The FDA has approved the subcutaneously injected
monoclonal antibody dupilumab (Dupixent – Sanofi/Regeneron) for add-on maintenance treatment of
patients ≥12 years old with moderate to severe
asthma with an eosinophilic phenotype or with oral
corticosteroid-dependent asthma. Dupilumab was
approved earlier to treat adults with moderate to
severe atopic dermatitis inadequately controlled with
topical therapies.
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019 (Issue 1566)
of this material is strictly prohibited.
For further information call: 800-211-2769
27
The Medical Letter ® Vol ...
Since 2008, because of safety concerns, the FDA has
mandated that long-term cardiovascular outcomes trials
be conducted for all new drugs for type 2 diabetes.
Reductions in the incidence of macrovascular complications
in these trials with some sodium-glucose
co-transporter 2 (SGLT2) inhibitors and glucagon-like
peptide 1 (GLP-1) receptor agonists in patients at risk
for cardiovascular disease (see Table 1) have led to
new recommendations.
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
The Medical Letter ® Vol. 61 (1573) June 3, 2019
ADVERSE EFFECTS — In the 6 placebo-controlled
clinical ...
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years.